Oakhillbio
31 employees on LinkedIn · 1 known investors
Oak Hill Bio is a clinical-stage biotechnology company that acquires and develops late-stage rare disease drugs deprioritized by larger pharmaceutical companies. Its lead program, rugonersen (OHB-724), is an investigational antisense oligonucleotide being developed as a treatment for Angelman syndrome, a neurodevelopmental disease.
Investors · 1
Frequently asked questions
- What does Oakhillbio do?
- Oak Hill Bio is a clinical-stage biotechnology company that acquires and develops late-stage rare disease drugs deprioritized by larger pharmaceutical companies. Its lead program, rugonersen (OHB-724), is an investigational antisense oligonucleotide being developed as a treatment for Angelman syndrome, a neurodevelopmental disease.
- Who are Oakhillbio's investors?
- Oakhillbio's investors include venBio Partners.